SARS-CoV-2 Antiviral Therapy.

Tao, Kaiming; Tzou, Philip L; Nouhin, Janin; Bonilla, Hector; Jagannathan, Prasanna; Shafer, Robert W

Tao, Kaiming; Tzou, Philip L; Nouhin, Janin; Bonilla, Hector; Jagannathan, Prasanna; Shafer, Robert W.

Afiliação

Tao K; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
Tzou PL; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
Nouhin J; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
Bonilla H; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
Jagannathan P; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.
Shafer RW; Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California, USA.

Clin Microbiol Rev ; 34(4): e0010921, 2021 12 15.

Article em En | MEDLINE | ID: mdl-34319150

Assuntos

COVID-19; SARS-CoV-2; Antivirais/farmacologia; Antivirais/uso terapêutico; Desenvolvimento de Medicamentos; Endopeptidases; Humanos

Palavras-chave

SARS-CoV-2; antiviral therapy; drug repurposing; monoclonal antibody; nucleoside analogs

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Revista: Clin Microbiol Rev Assunto da revista: MICROBIOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google